EGFR and head and neck squamous cell carcinoma: c-Met knockdown in vitro sensitizes EGFR to erlotinib, and c-Met inhibition also shows erlotinib sensitization in a dominant-active c-Src subset of EGFR overexpressing HNSCC lines [160].